AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2015
Aug 20, 2015
30016_dirs_2015-08-20_a3dae810-95d9-468b-9eca-5d89f6bee0e4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2015-08-18
Reporting Person: Williams Michael J PhD (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-08-18 | Common Stock | M | 6586 | $26.66 | Acquired | 36672 | Direct |
| 2015-08-18 | Common Stock | S | 6586 | $78.34 | Disposed | 30086 | Direct |
| 2015-08-18 | Common Stock | M | 3750 | $26.66 | Acquired | 33836 | Direct |
| 2015-08-18 | Common Stock | M | 5818 | $17.19 | Acquired | 39654 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-08-18 | Non-Qualified Stock Option (Right to buy) | $26.66 | M | 6586 | Disposed | 2017-02-13 | Common Stock (6586) | Direct |
| 2015-08-18 | Incentive Stock Option (Right to buy) | $26.66 | M | 3750 | Disposed | 2017-02-13 | Common Stock (3750) | Direct |
| 2015-08-18 | Incentive Stock Option (Right to buy) | $17.19 | M | 5818 | Disposed | 2016-02-13 | Common Stock (5818) | Direct |
Footnotes
F1: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $78.33 to $78.40, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
F2: Grant of option to buy shares of IDEXX Laboratories Inc. common stock that became exercisable as to 3,834 shares on 2/14/2011, 2/14/2012, 2/14/2013 and 2/14/2014 and the remaining 1,959 shares on 2/14/2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F3: Grant of option to buy 1,875 shares of IDEXX Laboratories, Inc. common stock that became exercisable on the fifth anniversary date (2/14/2015) of the date of grant, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 1 share on 02/14/2010 and 02/14/2013 and the remaining 2,909 shares on 02/14/2014, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.